Photocure ASA (FRA:PHS)

Germany flag Germany · Delayed Price · Currency is EUR
6.13
-0.05 (-0.81%)
Last updated: Jan 29, 2026, 8:16 AM CET
23.09%
Market Cap161.14M +25.4%
Revenue (ttm)45.87M +2.2%
Net Income180.73K -85.0%
EPS0.01 -85.2%
Shares Outn/a
PE Ratio891.60
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume46
Open6.13
Previous Close6.18
Day's Range6.13 - 6.13
52-Week Range4.23 - 6.65
Betan/a
RSI47.59
Earnings DateFeb 18, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]

Industry Pharmaceutical Preparations
Founded 1993
Employees 101
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PHS
Full Company Profile

Financial Performance

Financial numbers in NOK Financial Statements